BUZZ - TD Synnex shares fall after agreeing to acquire BlueStar
路透社2026/10/07 15:56October 7th – Technology distributor TD Synnex Corporation (SNX.N) shares fell 2.2%, closing at $272.49. SNX agreed to acquire BlueStar to expand its technology product line; specific terms were not disclosed. BlueStar is a specialized technology distributor with expertise in Automatic Identification and Data Capture (AIDC), Radio Frequency Identification (RFID), mobile technologies, and Point-of-Sale (POS) technologies. The company stated that the transaction is expected to offer SNX customers and suppliers a broader portfolio of technology products, resources, and expertise. SNX said that prior to the completion of the transaction, both SNX and BlueStar will continue to operate independently, depending on regulatory approval. Including today’s move, SNX shares have gained 81.4% year-to-date. (For the convenience of non-English speakers, Reuters offers automated translations of its reports into several languages. Automated translation may contain inaccuracies or lack desired context and is provided solely for reader convenience. Reuters accepts no responsibility for any damage or loss caused by the use of automated translation.)
October 7 - ** Technology distributor TD Synnex Corporation (SNX.N) shares fell 2.2% to close at $272.49
** SNX (link) agreed to acquire BlueStar to expand its technology portfolio; specific terms were not disclosed
** BlueStar is a specialized technology distributor with expertise in automatic identification and data capture (AIDC), radio-frequency identification (RFID), mobile technologies, and point-of-sale (POS) technologies
** The company stated that the transaction is expected to allow SNX's customers and suppliers to access a broader range of technology products, resources, and expertise
** SNX said that until the deal is completed, the company and BlueStar will continue to operate independently, pending regulatory approval
** Including today's movement, SNX's cumulative gain so far this year is 81.4%
(For the convenience of non-native English speakers, Reuters has automated the translation of its reports into several other languages. As automated translation may contain errors or lack the necessary context, Reuters does not guarantee the accuracy of the automated translation. The automated translation is provided for readers’ convenience only. Reuters accepts no responsibility for any harm or loss arising from use of the automated translation.)
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Three-year remission rate up to 94%! Johnson & Johnson (JNJ.US) Tremfya Crohn's disease study shows positive long-term results
Long-term data from two Phase 3 clinical trials by Johnson & Johnson show that adult Crohn's disease patients treated with Tremfya (guselkumab) achieved a clinical remission rate of up to 94% over three years.
Kroger (KR.US) faces the largest layoffs in 143 years: cutting one-third of positions, more than 3,000 employees to be let go
Kroger has laid off 3,000 employees, accounting for more than one-third of its total workforce, marking the largest layoff in its 143-year history. The resources saved will be redirected towards price reductions and frontline operations.
RBA Minutes: Case for rates to act promptly to keep inflation expectations anchored
Crypto prices
More
